Effects of glycosylated hemoglobin on vascular responses in vitro.

Cardiovasc Res

Department of Internal Medicine, University of Iowa, Iowa City, USA.

Published: April 1997

Unlabelled: Vascular responses to endothelium-dependent vasodilators are greatly impaired in vivo, while isolated blood vessels from animals with diabetes mellitus demonstrate less consistent degrees of impairment. Glycation of proteins, such as hemoglobin, has been implicated in the vascular abnormalities associated with diabetes.

Objective: The purpose of this study was to test the hypothesis that glycosylated hemoglobin is capable of reducing endothelium-dependent vasodilator responses, possibly explaining impaired dilation observed in vivo.

Methods: To test this hypothesis, the effect of glycosylated hemoglobin (GH) on vascular responses was studied in several vascular beds, including ventricular microvessels and coronary, mesenteric, femoral, and renal arteries. Coronary arterioles were isolated and mounted between two glass pipettes in a pressurized (30 cmH2O) organ chamber. Isolated artery segments were studied using a standard isometric ring technique.

Results: In ventricular microvessels, 10 nM nGH (non-GH) and GH both attenuated the relaxation to Ach. A lower concentration, 1 nM nGH or GH, did not alter dilation to Ach. In coronary, femoral, mesenteric and renal artery segments, endothelium-dependent responses were not altered by the presence of 10 or 100 nM nGH or GH.

Conclusion: In coronary microvessels, and coronary, femoral, mesenteric and renal arteries, GH is not responsible for the impaired endothelial function associated with diabetes mellitus.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0008-6363(97)00016-3DOI Listing

Publication Analysis

Top Keywords

glycosylated hemoglobin
12
vascular responses
12
hemoglobin vascular
8
diabetes mellitus
8
test hypothesis
8
hypothesis glycosylated
8
ventricular microvessels
8
microvessels coronary
8
renal arteries
8
artery segments
8

Similar Publications

Objectives: This analysis quantifies the potential long-term clinical and cost benefits of early and intensive metabolic control (EIMC) versus conventional management in patients newly diagnosed with type 2 diabetes in Italy.

Methods: The PRIME T2D Model was used to project clinical and cost outcomes over long-term time horizons for a newly diagnosed cohort of patients receiving EIMC or conventional management. EIMC was associated with a mean glycated hemoglobin reduction of 0.

View Article and Find Full Text PDF

Objective: This study aims to investigate the correlation between the development of diabetic retinopathy (DR) and the changes in corneal sub-basal nerve plexus (SNP) and corneal dendritic cells (DCs).

Methods: 58 patients with type 2 diabetes mellitus (T2DM) and 30 age- and sex-matched healthy participants underwent assessment of the corneal nerve. The DR group was divided into no diabetic retinopathy (NDR) and 29 eyes with mild to moderate non-proliferative diabetic retinopathy (NPDR).

View Article and Find Full Text PDF

Impact of general practitioner appointment frequency on disease management in type 2 diabetes mellitus patients.

Prim Care Diabetes

January 2025

Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain; Department of Medicine. University of Oviedo, Oviedo, Spain; Servicio de Endocrinología y Nutrición, Hospital Universitario Central de Asturias, Oviedo, USA.

Aims: We investigated the association between the frequency of visits to general practitioners (GPs) and the degree of disease control in patients with T2DM.

Methods: This study included patients diagnosed with T2DM who visited their GPs between 2014 and 2018. A total of 89,674 patients, accounting for 1,203,035 visits, were included.

View Article and Find Full Text PDF

Background: Diabetes mellitus is a growing global health issue, especially in low- and middle-income countries like Ethiopia. To the best of our knowledge, the impact of diabetes knowledge on glycemic control in Ethiopia has not been documented. This study assessed diabetes knowledge and its relationship with glycemic control among Type 2 diabetes (T2DM) patients in Debre Berhan, Ethiopia.

View Article and Find Full Text PDF

Alpelisib is a phosphatidylinositol 3-kinase inhibitor approved by the US Food and Drug Administration for the treatment of hormone receptor-positive metastatic breast cancer with (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α) mutation. In recent years a number of adverse effects have been observed to be associated with this therapy, the most notable of which is hyperglycemia. A literature search was conducted to include case studies, case series, systematic reviews, and meta-analyses within the last 10 years that evaluated patients with mutated hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!